trial

A Clinical Trial on the Antipsychotic Properties of Cannabidiol

NCTId NCT00309413
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 29 (actual)
Sponsored by University of Cologne
Primary completion 2008-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2006-03
Primary completion
2008-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
—

Sponsors

University of CologneLead Sponsor
Stanley Medical Research InstituteCollaborator
Coordinating Centre for Clinical Trials CologneCollaborator

Investigators

1
F. Markus Leweke, MDPrincipal Investigator

Sites

1 total
Cologne, Germany

Linked catalysts

1
A Clinical Trial on the Antipsychotic Properties of Cannabidiol — primary completion2008-03

Facts & assertions

4 sourced
Enrollment
29
Phase
PHASE2
Primary Completion Date
2008-03
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
University of Cologne
company
collaborator
Stanley Medical Research Institute
company
Coordinating Centre for Clinical Trials Cologne
company
indication
Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Psychotic Disorders
indication
investigator
F. Markus Leweke, MD
person